Cargando…
Sugammadex: clinical development and practical use
Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a mu...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Anesthesiologists
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888841/ https://www.ncbi.nlm.nih.gov/pubmed/24427454 http://dx.doi.org/10.4097/kjae.2013.65.6.495 |
_version_ | 1782299116252954624 |
---|---|
author | Fuchs-Buder, Thomas Meistelman, Claude Raft, Julien |
author_facet | Fuchs-Buder, Thomas Meistelman, Claude Raft, Julien |
author_sort | Fuchs-Buder, Thomas |
collection | PubMed |
description | Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine. |
format | Online Article Text |
id | pubmed-3888841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | The Korean Society of Anesthesiologists |
record_format | MEDLINE/PubMed |
spelling | pubmed-38888412014-01-14 Sugammadex: clinical development and practical use Fuchs-Buder, Thomas Meistelman, Claude Raft, Julien Korean J Anesthesiol Review Article Sugammadex is belonging to a new class of drugs: the selective relaxant binding agents. Sugammadex can reverse residual paralysis by encapsulating free circulating non depolarizing muscle relaxants. The mains advantages of sugammadex when compared with conventional anticholinesterase agents are a much faster recovery time and the unique ability, for the first time, to reverse rapidly and efficiently deep levels of neuromuscular blockade. However it only works for reversal of rocuronium or vecuronium-induced neuromuscular blockade. When administered 3 min after rocuronium the use of a large dose (16 mg/kg) can even reverse rocuronium significantly faster than the spontaneous recovery after succinylcholine. The Korean Society of Anesthesiologists 2013-12 2013-12-26 /pmc/articles/PMC3888841/ /pubmed/24427454 http://dx.doi.org/10.4097/kjae.2013.65.6.495 Text en Copyright © the Korean Society of Anesthesiologists, 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Fuchs-Buder, Thomas Meistelman, Claude Raft, Julien Sugammadex: clinical development and practical use |
title | Sugammadex: clinical development and practical use |
title_full | Sugammadex: clinical development and practical use |
title_fullStr | Sugammadex: clinical development and practical use |
title_full_unstemmed | Sugammadex: clinical development and practical use |
title_short | Sugammadex: clinical development and practical use |
title_sort | sugammadex: clinical development and practical use |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888841/ https://www.ncbi.nlm.nih.gov/pubmed/24427454 http://dx.doi.org/10.4097/kjae.2013.65.6.495 |
work_keys_str_mv | AT fuchsbuderthomas sugammadexclinicaldevelopmentandpracticaluse AT meistelmanclaude sugammadexclinicaldevelopmentandpracticaluse AT raftjulien sugammadexclinicaldevelopmentandpracticaluse |